anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants are recruited via the 'Knowledge Centre Anxiety and Stress in youth' (KAS) telephone line, by a research assistant or via the waiting list of LUBEC. Following recruitment, a research assistant conducts a screening call with the parent(s) lasting approximately half an hour to determine the child\'s eligibility for the project. Subsequently, the research assistant collaborates with a therapist from KAS/LUBEC to evaluate the case. If both agree that the child meets the criteria of the \'Learn to Dare!\' program, the research assistant proceeds to conduct a diagnostic interview with both the child and parents. When the child still meets the requirements for \'Learn to Dare!\', the therapist from LUBEC, who is going to give the trainings, will do an intake with the child and parents.

When the child still meets the criteria after this intake, a subsequent appointment will take place at LUBEC in Leiden, that serves as an opportunity for parents and children to familiarize themselves with the therapist and complete the baseline 1 measurement. This appointment will take about 1,5-2 hours. Two research assistants will administer questionnaires to the parent(s) and the child: demographics questionnaire, SCARED, CDI, WIRK-ALL. In addition, they will administer the anxiety scale of the SCID in combination with the ADIS severity index to the parent(s) and the child.

After baseline 1, there will be a waiting period of 4 weeks. After this period, the child and parents complete the SCARED questionnaire online (30 minutes) before commencing the treatment phase. The treatment comprises eight group sessions of \'Learn to Dare!\' (one session per week; 1.5 hours each) along with assigned homework. After those eight weeks of treatment, the post-treatment session will take place at LUBEC (1,5-2 hours). The therapist will meet with the child and the parent(s) to evaluate the treatment together. The research assistants will administer the anxiety scale of the SCID in combination with the ADIS severity index to the parent(s) and the child. In addition, a couple of questionnaires will be administered: SCARED, CDI, WIRK-ALL, Training Evaluation Questionnaire. Lastly, there will be three follow-ups 6, 12, and 24 months after treatment (1,5 hours per follow-up). Parents have the option to conduct these follow-ups either at LUBEC or online. The anxiety scale of the SCID, along with the severity index of the ADIS questionnaire, is administered, along with supplementary questionnaires: SCARED, CDI, WIRK-ALL.
A novel sleep regulating pharmaceutical formulation is introduced, typically implementing two principal drugs having actions which are reversive to one another, yet incorporated into a unitary solid dosage, and prepared for oral administration before bedtime. Usually, structure is configured to initially release a calmative or other sleep-compatible substance by prompt dissolution. The initial release is followed by a specific period of delay, which in basic formulations entails no release of any drug, and which allows a nominal interval of sleep. At the terminus of the delay, a final agent is released to induce wakeup. Incorporation of agents of opposite action within a unitary dosage form renders utility which is uniquely appropriate to the invention. In a preferred embodiment, delay of release and final delivery of wakeup agent are arranged by a dialysis membrane which eventually bursts as a result of osmotic pressure generated by a hydrophilic core.
Participants will receive 4 sessions across 8 weeks with a later booster session and hearing aid fitting. Each session will take \~75 minutes.
Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.
NEW MATERIAL:A platinum diamine complex expressed by formula I [R1-R4 are H or lower chain alkyl and are not wholly H at the same time; n is 2 or 3; formula II is formula III-VII (m is 1 or 2; R5 and R6 are H or lower alkyl)]. EXAMPLE:cis-Oxalato-N-methylethylenediamineplatinum. USE:An antitumor agent, having low renal toxicity and high solubility in water and stable at room temperature. PREPARATION:For example, a tetrahalogenato-platinum salt expressed by the formula M2Pt(Hal)4 (M is a group capable of being monovalent cation, e.g. K, Na, etc.; Hal is halogen) is reacted with an amine expressed by formula VIII in water to give a dihalogenato-amineplatinum expressed by formula IX, which is then reacted with silver nitrate in water to afford an aqueous solution of a diaquo complex expressed by formula X. The resultant aqueous solution is further reacted with a dicarboxylic acid salt to give the aimed dicarboxylate complex. The reaction is preferably carried out at room temperature - 90 deg.C.
PURPOSE: A CIB1(calcium and integrin binding protein 1) protein and gene suppressing apoptosis is provided to treat disease regarding apoptosis and selective suppression of ASK1 protein. CONSTITUTION: A composition for preventing or treating diseases regarding apoptosis contains human CIB1 protein as an active ingredient. The CIB 1 protein is denoted by sequence number 1. The CIB 1 protein is encoded by the gene of sequence number 2. The diseases are neural disorder, cancer, or immune diseases. The neural disorder is neurodegenerative disorder. The immune disease is rheumatoid arthritis, psoriasis, or asthma.
The present invention relates to a drug for treating bacterial vaginosis, particularly to a medicinal composition for treating the bacterial vaginosis. The bacterial vaginosis is one of common gynecological vaginal infectious diseases, which accounts for 40 to 50% of vulva infections, and the ages of patients with the bacterial vaginosis are from 15 to 44 or so; the bacterial vaginosis is relevant to cervical atypical hyperplasia, and the women with the cervical atypical hyperplasia has twice the morbidity of normal women. Besides, the bacterial vaginosis can cause other gynecological syndromes. At present, antibiotics are usually used for treating the bacterial vaginosis, but the effect of the antibiotics is not good, and the relapse rate of the bacterial vaginosis is high; the treatment of the bacterial vaginosis is a problem which is clinically not solved for many years. The drug of the present invention is prepared from components of the following proportion by weight: 100 to 120 of astragalus extract, 80 to 120 of licorice extract and 70 to 100 of flavescent sophora extract. The present invention has the advantages of pain and itch elimination at high efficiency and a high speed, vagina dysbacteriosis adjustment, no relapse during the treatment of the bacterial vaginosis and little side effect.
OBJECTIVE: People commonly cope with chronic low back pain (cLBP) by ignoring and distraction. Can mindful interoceptive exposure to the pain sensation itself and its phenomenological components be an alternative approach?
METHODS: Single-arm feasibility study in patients with cLBP using a 2-minute attention exercise guided by a smartphone app several times per day over 8 weeks. We assessed feasibility, pre/post pain, function, and psychological parameters using mixed methods: standard questionnaires, ecological momentary assessment, and exit interviews that included micro-phenomenology technique and subsequent reflexive thematic qualitative analysis.
RESULTS: We enrolled 31 participants, mostly female, mean age 48, the majority had pain for >5 years; 29 completed. Mean pain intensity [0-10] improved from 4.8 ±1.7 to 3.1 ±1.9 (p < .0001); mean PEG scores (intensity and interference with daily life; range 0-30) improved from 13.7 ±6.2 to 8.4 ±6.6 (p < .0001); pain impact (9 items incl physical function) 22.3 ±8.7 to 19.7 ±8.1 (p = .0010). Twenty-one of 29 improved PEG score ≥30%. There were significant improvements in PCS Rumination and MAIA Not-Worrying. Participants became aware of their usual habit of avoidance and the challenge of and resistance to focusing on pain. They were surprised how pain sensations varied over time, and that pain intensity and the threat value of pain could diminish by focusing on it. They described a variety of 3D pain shapes (e.g., football, pool ball, rod, nail, brick, stars) with a range of colors, transparency, temperature, and density that for some changed with mindful attention. Most struggled to find appropriate words for sensory awareness and attention regulation and found that the threat value of their pain diminished.
CONCLUSIONS: Mindful interoceptive exposure to the sensations of their cLBP using a 2-minute attention exercise with a phone app-rather than ignoring and distracting from it-may be a beneficial intervention for cLBP.
TRIAL REGISTRATION: ClinicalTrials.gov #NCT06186193.
Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
OXAPROZIN CAPSULES (oxaprozin) is a nonsteroidal anti-inflammatory drug, available as capsules of 300 mg for oral administration. The chemical name is 4,5-diphenyl-2-oxazole-propionic acid. The molecular weight is 293.32 g/mol. Its molecular formula is C18H15NO3, and it has the following chemical structure.

Oxaprozin is a white to off-white powder with a slight odor and a melting point of 162°C to 163°C. It is slightly soluble in alcohol and insoluble in water, with an octanol/water partition coefficient of 4.8 at physiologic pH (7.4). The pKa in water is 4.3.

The inactive ingredients in OXAPROZIN CAPSULES include: microcrystalline cellulose, pregelatinized corn starch, hypromellose 2910, sodium starch glycolate, stearic acid, and silicon dioxide. OXAPROZIN CAPSULES 300 mg capsules are white opaque capsules imprinted “403” on the cap in black ink.
Sudden out-of-hospital cardiac arrest (OOH-CA) remains a significant cause of death, in spite of recent declines in overall mortality from cardiovascular disease. Several studies document sub optimal quality of manual chest compressions and this may influence outcome. However, studies comparing manual and mechanical chest compressions have resulted in conflicted results. The investigators think this may be based on methodology and design issues of the trials as much as not focusing on training and experience in operating a mechanical device clinically. Therefore the investigators will focus on these issues and implement three phases in the study (In field training, Run In phase, and Study phase). The investigators will also focus on early use of mechanical CPR after arrival at patient side and randomization at arrival. In order to achieve this the investigators will follow the Norwegian CPR Guidelines with 3 min CPR before defibrillation and the 3 min algorithm. Quality of CPR will be monitored.
FIELD: medicine, chemical- -pharmaceutical industry, pharmacy. SUBSTANCE: invention relates to development of preparations used for treatment of wide-spread dermatosis, among them psoriasis. Birch tar-base medicinal agent comprises phenols, organic acids, their esters and polycyclic aromatic hydrocarbons that is standardized by phenol with definite content of meta-cresol-guaiacol and salicylic acid. Content of polycyclic hydrocarbon 3,4- benzopyrene doesn't exceed 1 mcg/g. Invention involves method for preparing agent from freshly distilled out birch tae by its purification, moisture removing that is used for treatment of dermatosis. Method for treatment of skin diseases involves application of tar on damaged sites by cutaneous route for 5-30 min followed by its washing out. Invention provides the development of therapeutically more effective preparation with reduced amount adverse effects. EFFECT: improved preparing and treatment methods, valuable medicinal properties of agent. 5 cl, 3 tbl, 4 ex
Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-14 and undergo surgery on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity. In circumstances where there are medical or administrative reasons for delaying surgery, treatment with IDO1 inhibitor INCB024360 may continue for up to 3 weeks.
INTRODUCTION: Haemodialysis (HD) patients usually engage in a low level of physical activities, which could impact the prognosis and mortality of this group. Fitness Qigong Baduanjin, a physical exercise from traditional Chinese Medicine, is known to have benefit in chronic heart failure patients and peritoneal dialysis patients. However, researches about Baduanjin in HD patients are currently limited. So, the aim of the study is to investigate the current exercise intensity of HD patients and its influencing factors, and to explore the effects of Baduanjin on HD patients.
METHODS AND ANALYSIS: This prospective, non-blinded, randomised controlled trial will enrol patients with end-stage kidney disease who were stable on HD for more than 3 months. All eligible participants will be randomly divided into the intervention group undergoing Baduanjin and the control group without Baduanjin in a 1:1 ratio. The intervention group is required to perform Baduanjin two times per day, starting 30 min after breakfast and dinner, 45 min per session for a total of a 6 month, starting from 10 June 2024. Information such as laboratory biochemical examination indicators, radiological examination results and related scales and questionnaires will be collected at baseline, 1 month follow-up, 3 month follow-up and 6 month follow-up. All statistical tests are conducted through the two-tailed test, and a p-value≤0.05 will be considered statistically significant for the difference being tested. The description of quantitative indicators will be used in calculating the number of cases, mean, SD, median and IQR method. The classification indicators will be used to describe the number of cases and percentages (frequency and frequency rate).
ETHICS AND DISSEMINATION: The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University (V20230521). The results will be reported in a peer-reviewed journal and a relevant academic conference.
TRAIL REGISTRATION: ChiCTR2300074659.
The invention relates to cyclochrome-propane-casein-iso-leu-phenylpropanoid (Trp-Ala-Tyr-Ile-Phe cyclic peptide) with hepatoma cytotoxicity and alpha-glucosidase inhibitory activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclic-propyl-casein-iso-leu-phenylpropanoid is fifteen-membered cyclic pentapeptide formed by connecting tryptophan, alanine, tyrosine, isoleucine and phenylalanine through an amide bond. This is a novel compound and has not been reported in the literature. The compound can be obtained by culturing frog-feces mould, and then extracting and separating. The pure product of the cyclochrome-propane-casein-iso-brightness-phenylpropanoid is white powder, the half inhibitory concentration (IC  50 ) on hepatoma cell HepG2 was: the half inhibitory concentration (IC  50 ) of alpha-glucosidase at 20.21 μg/mL: 73.52 μg/mL. The compound can be used as potential medicine for treating liver cancer and slimming medicine.
Primary aldosteronism (PA) is the most frequent cause of endocrine hypertension, with an estimated prevalence of 20% among individuals with resistant hypertension. PA is associated with an increased risk of malignancy, probably due to aldosterone effects in promoting cell proliferation. Recently, a high prevalence of PA was demonstrated in patients with essential hypertension (EH) and papillary thyroid cancer (PTC), similarly to the prevalence of PA among individuals with resistant EH. In addition, abnormalities in thyroid ultrasound (non-toxic multinodular goiter) are more common in PA patients when compared to controls. Despite of this initial evidence, the link between PA and PTC remains to be elucidated. Then, the aim of this study is to investigate the clinical and genetic aspects of the association between PA and PTC. The specific aims are: 1) To evaluate the prevalence of PA in a transversal cohort of patients with EH and PCT; 2) To investigate thyroid ultrasonography abnormalities in PA patients; 3) To perform exome sequencing (blood DNA) in patients with PA and PTC paired with tumor tissue; and 4) To conduct functional studies of the novel genetic variants identified by exome sequencing. To achieve this goal, the investigators will employ the following techniques: next-generation sequencing, bioinformatic analysis, real-time PCR and immunohistochemistry. In this project, the investigators expect to establish the prevalence of PA among patients with EH and PTC, and to identify new genetic targets involved in the association between PA in PTC.
BACKGROUND: Patients undergoing caesarean delivery are at risk of developing unintended perioperative hypothermia, defined as a core temperature <36.0°C. Most previous studies of core temperature in caesarean delivery patients have not been conducted with accurate measurements for the complete perioperative period. Therefore, we conducted a prospective observational study to identify the incidence and duration of pre- and post-operative maternal hypothermia with a high accuracy continuous temperature monitoring system.
METHODS: Women ≥18 years old presenting for elective caesarean delivery under spinal anaesthesia were invited to participate in the study. The primary outcomes were the incidence and duration of perioperative maternal hypothermia (<36.0°C). Maternal core temperatures were measured with the non-invasive zero-heat-flux thermometer (Bair Hugger Temperature Monitoring System, 3M) throughout the perioperative course.
RESULTS: A total of 40 participants were recruited to the study. The incidence of perioperative hypothermia was 32.5%, with a duration of 77 ± 40 min (mean ± standard deviation). The hypothermic patients had similar core temperature as the normothermic patients at baseline preoperatively, but significantly lower temperature at operating room arrival and during the remaining study period. Forty percent of all patients reported thermal discomfort and felt cold on admission to post anaesthesia care unit, whereas 33% had shivering. Neither thermal discomfort nor shivering were associated with hypothermia.
CONCLUSION: In the present study almost a third of the women undergoing elective caesarean delivery developed perioperative hypothermia with a core temperature <36.0°C. The mean duration of maternal hypothermia was 77 min, lasting well into the postoperative period for many patients. These data should remind healthcare professionals of the importance of measuring core temperature in all phases of the perioperative setting and to consider optimal warming measures to avoid and treat hypothermia.
The invention provides an isolated, purified population of human cells comprising CD8 +  T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8 +  T cells, (b) reducing Cbl-b activity in the CD8 +  T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8 +  T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.
1,188,656. Anabolic substance from haemolysed blood W. HELMBOLD. 20 April, 1967 [20 April, 1966], No. 18146/67. Heading A5B. [Also in Division C1]  A substance having growth promoting and anabolic activity is prepared by fractionating a haemolysate of the blood cells from the blood of young animals, by one or more of: ion exchange, absorption chromatography preparative high voltage electrophoresis, high voltage electrodialysis, gel filtration, preparative thin-layer chromatography and counter current distribution, and isolating the substance from the fraction having an ultra-violet absorption maximum at 245-246mu. The starting material is preferably spray-dried haemolysed blood, and the fractionation is preferably preceded by ultra filtration, e.g. through a high pressure membrane filter permeable to molecules up to mol. wt. of 10,000, to filter out high molecular weight impurities. Suitable chromatographic agents are dextran or cellulose based anion exchangers, or anion exchange synthetic resins or hydroxy-apatite. Counter current distribution may be effected in propanol or butanol, and thin layer chromatography is performed on silica gel with a butanol/acetic acid/water system. The substance is a water soluble anionic compound having a molecular weight of less than 700, and is not a peptide, sugar, lipid, nucleoside or nucleotide. It has the same electrophoretic mobility as serum albumin at pH 8.6; an Rf-value of 0.93-0.96 in butanol/acetic acid/water 0:1:1 on silica gel; and the following U.V. absorption maxima: 245-246 mÁ at neutral pH; 250-260 mn (255.5 mÁ at pH 2.0; and 280-281mÁ at pH 12.0. Compositions comprising the substance together with a carrier are used for pharmaceutical application or for stimulating the growth of crops (see Division C1). Pharmaceutical compositions suitably contain the active substance in such a concentration that, after 20 fold dilution with water, they have an extinction coefficient of at least 0.6 at 246 mÁ.
OBJECTIVE: Emerging evidence supports that brain dysfunction may be attributable to environmental factors. This study aims to examine associations of ambient temperature and temperature variability (TV) with seizure incidence in children, which has not been explored.
MATERIAL AND METHODS: Data on 2718 outpatient visits due to seizure were collected in Shanghai, China, from 2018 to 2023. Exposure to ambient temperature was estimated at children's residential addresses using spatial-temporal models. A time-stratified case-crossover design with a distributed lag non-linear model (DLNM) was conducted to assess the association between seizure incidence and daily average of ambient temperature over a period of 21 days prior to a case date of disease onset. For a given case date, we selected all dates falling on the same day of the week within the same month as control dates. We calculated a composite index of intra-day and inter-day TV, which was the standard deviation of the daily minimum and maximum temperatures, respectively, over 7 days preceding a case date. We then assessed the association between TV and seizure incidence. Stratified analyses were conducted by age (73.51% < 5 years old and 26.49 % ≥ 5 years old), sex (41.83% female), presence of fever (69.72%), and diagnosis of epilepsy (27.63%).
RESULTS: We observed inversed J-shaped temperature-response curves. Lower temperatures had a significant and prolonged effect than higher temperatures. Using 20 °C (with the minimum effect) as the reference, the cumulative odds ratios (ORs) for over 0-21 days preceding the onset at the 5th percentile of the temperature (3 °C) and at the 95th percentile (29 °C) were 3.17 (95% CI: 1.77, 5.68) and 1.54 (95% CI: 0.97, 2.44), respectively. In addition, per 1 °C increases in TV0-7 was associated with OR of 1.08 (95% CI: 1.01, 1.15). Older children and those experiencing seizure with fever exhibited a higher risk of seizure onset at both lower and higher ambient temperatures.
CONCLUSION: Both low and high temperatures can contribute to the morbidity related to pediatric seizure. Lower temperatures, however, exerted a longer period of effect prior to seizure onset than higher temperatures. An increased risk for incident seizure was significantly associated with temperature variability during preceding 7 days.